1-10 of about 34 results
Item icon
50 mg, 150 mg, and 250 mg NUVIGIL® under license beginning in June 2016, or earlier … NUVIGIL® is an FDA-approved prescription medicine used to improve wakefulness in …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1688889View duplicates

Item icon
mg, and 250 mg dosages of NUVIGIL®. The settlements allow Actavis to launch generic … 50 mg, 150 mg, and 250 mg NUVIGIL® under license beginning in June 2016, or earlier …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1940346View duplicates

Item icon
The Official TEVA News Releases - Investor Relations web site. Teva is the global leader in generic pharmaceuticals and has one of the broadest product portfolios in the industry …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-news&nyo=0

Item icon
continue to focus on our current NUVIGIL® indications and we remain committed to … insomnia. Full prescribing information for NUVIGIL® is available at www.NUVIGIL.com. …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1851019View duplicates

Item icon
The National Network of Excellence in Neuroscience (NNE) … treatment of Parkinson's disease; and NUVIGIL(R) (armodafinil) Tablets [C-IV], used … Study results providing data on the …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1684340View duplicates

Item icon
Final Phase III Study of Armodafinil (NUVIGIL®) in Patients with Major Depression Associated … Phase III clinical study for armodafinil (NUVIGIL®) as adjunct therapy in adults with …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsclinical&nyo=1View duplicates

Item icon
TEVA Investor Relations - Teva Reports Third Quarter 2012 Results … The National Network of Excellence in Neuroscience (NNE) … Net Revenues Total $5.0 Billion, up 14% …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1752738View duplicates

Item icon
TEVA Investor Relations - Teva Reports Third Quarter 2013 Results … The National Network of Excellence in Neuroscience (NNE) … Non-GAAP EPS of $1.27, GAAP Diluted EPS of $0.84 …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1870794View duplicates

Item icon
The National Network of Excellence in Neuroscience (NNE) … Fourth Quarter Net Revenues Total $5.7 Billion, up 28%, with Non-GAAP EPS of $1.59, up 27% …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1661157View duplicates

Item icon
TEVA Investor Relations - Teva Reports Second Quarter 2012 Results … The National Network of Excellence in Neuroscience (NNE) … Net Revenues Total $5.0 Billion, up 19% …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1721484View duplicates